Top Ten Tips Regarding Fiduciary Obligations to Compliance for Life Sciences Boards
Event summary
Recent case law provides insight into the type of red flags that are sufficient to overcome the high standard established in the Caremark case for a claim of breach of fiduciary obligations. Regulatory and enforcement authorities have through the years articulated expectations regarding regulatory compliance for governing bodies in the health care ecosystem. Recent updates to these guidances offers additional insights.
Please join us for an interactive discussion of the practical considerations for satisfying fiduciary standards relating to compliance oversight.
For more information, please email Savannah Euler.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.